Skip to main content
RYTM
NASDAQ Life Sciences

试验期Setmelanotide 3达到主要终点，BMI降低16.4％；PDUFA日期定于3月20日

feedReported by Reuters
Sentiment info
Positive
Importance info
9
Price
$92.66
Mkt Cap
$6.332B
52W Low
$45.905
52W High
$122.2
Market data snapshot near publication time

summarizeSummary

Rhythm Pharmaceuticals宣布了Setmelanotide在获得性下丘脑肥胖患者中的额外阳性3期数据，实现了主要终点，BMI显著降低了16.4％。同时，公司确认了该药物的PDUFA目标日期为2026年3月20日。这一消息具有很高的材料性，尤其是达到主要终点的阳性3期结果，具有强大的临床结果，显著降低了该药物的监管风险，并提高了其商业前景。确认的PDUFA日期提供了一个明确的、近期的催化剂，可能会推动FDA批准决策，这预计将推动大量股票移动。交易者现在将密切关注FDA在指定的PDUFA日期之前的决定。

في وقت هذا الإعلان، كان RYTM يتداول عند ‏٩٢٫٦٦ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٦٫٣ مليار US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ‏٤٥٫٩١ US$ و‏١٢٢٫٢٠ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٩ من 10. المصدر: Reuters.

show_chartPrice Chart

Share this article

Copied!

feed RYTM - Latest Insights

RYTM
Apr 03, 2026, 3:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Rhythm Pharma Appoints Biotech Veteran Kimberly Popovits to Board, Mathers Resigns
Sentiment: Positive
View Wiseek Article
RYTM
Mar 26, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Rhythm Pharma's IMCIVREE Receives Positive EU Opinion for Hypothalamic Obesity, Expanding Global Market
Sentiment: Positive
View Wiseek Article
RYTM
Mar 26, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Positive CHMP Opinion for IMCIVREE Expands Rhythm Pharma's European Market Opportunity for Hypothalamic Obesity
Sentiment: Positive
View Wiseek Article
RYTM
Mar 20, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
9
FDA Approves IMCIVREE for Acquired Hypothalamic Obesity, Expanding Market for First-Ever Therapy
Sentiment: Positive
View Wiseek Article
RYTM
Mar 19, 2026, 6:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
FDA Approves IMCIVREE for Acquired Hypothalamic Obesity, First & Only Therapy for Rare Disease
Sentiment: Positive
View Wiseek Article
RYTM
Mar 16, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Rhythm Pharma's Setmelanotide Phase 3 EMANATE Trial Misses Primary Endpoints, Post Hoc Data Shows Promise
Sentiment: Negative
View Wiseek Article
RYTM
Mar 02, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
8
Rhythm Pharma Reports Strong Additional Phase 3 Data for Setmelanotide in Hypothalamic Obesity Ahead of PDUFA Date
Sentiment: Positive
View Wiseek Article
RYTM
Mar 01, 2026, 12:31 PM EST
Source: Reuters
Importance Score:
9
Setmelanotide Phase 3 Trial Hits Primary Endpoint with 16.4% BMI Reduction; PDUFA Date Set for March 20
Sentiment: Positive
View Wiseek Article
RYTM
Mar 01, 2026, 12:30 PM EST
Source: GlobeNewswire
Importance Score:
9
Expanded Phase 3 Data for Setmelanotide Reveals 18.8% BMI Reduction in Hypothalamic Obesity
Sentiment: Positive
View Wiseek Article
RYTM
Feb 26, 2026, 6:11 PM EST
Source: Reuters
Importance Score:
7
Rhythm Pharmaceuticals Files For Mixed Shelf
Sentiment: Negative
View Wiseek Article